Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
STOK Stoke Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: STOK
Price (delayed)
$8.99
Market cap
$490.83M
P/E Ratio
10.58
Dividend/share
N/A
EPS
$0.85
Enterprise value
$215.93M
Stoke Therapeutics, is a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines. Using the company's proprietary TANGO (Targeted Augmentation of
Highlights
Stoke Therapeutics's net income has surged by 156% QoQ and by 146% YoY
The EPS has soared by 152% from the previous quarter and by 135% YoY
Key stats
What are the main financial stats of STOK
Market
Valuations
Earnings
Shares outstanding
54.6M
Market cap
$490.83M
Enterprise value
$215.93M
Price to earnings (P/E)
10.58
Price to book (P/B)
1.39
Price to sales (P/S)
2.72
EV/EBIT
5.62
EV/EBITDA
5.04
EV/Sales
1.13
Revenue
$190.91M
Gross profit
$190.91M
Operating income
$38.24M
Net income
$50.27M
EBIT
$38.45M
EBITDA
$42.86M
Free cash flow
$69.2M
Per share
Balance sheet
Liquidity
EPS
$0.85
EPS diluted
$0.8
Free cash flow per share
$1.2
Book value per share
$6.47
Revenue per share
$3.3
TBVPS
$7.03
Total assets
$406.89M
Total liabilities
$56.81M
Debt
$0
Equity
$350.07M
Working capital
$331.05M
Debt to equity
0
Current ratio
8.41
Quick ratio
8
Net debt/EBITDA
-6.41
Margins
Efficiency
Dividend
EBITDA margin
22.4%
Gross margin
100%
Net margin
26.3%
Operating margin
20%
Return on assets
15.7%
Return on equity
19.1%
Return on invested capital
43.5%
Return on capital employed
10.6%
Return on sales
20.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
STOK stock price
How has the Stoke Therapeutics stock price performed over time
Intraday
0.67%
1 week
3.81%
1 month
18.92%
1 year
-29.77%
YTD
-18.5%
QTD
35.19%
Financial performance
How have Stoke Therapeutics's revenue and profit performed over time
Revenue
$190.91M
Gross profit
$190.91M
Operating income
$38.24M
Net income
$50.27M
Gross margin
100%
Net margin
26.3%
Stoke Therapeutics's net income has surged by 156% QoQ and by 146% YoY
The company's operating income has surged by 138% QoQ and by 132% YoY
STOK's net margin has surged by 111% since the previous quarter and by 102% year-on-year
The operating margin has soared by 107% from the previous quarter and by 101% YoY
Price vs fundamentals
How does STOK's price correlate with its fundamentals
Growth
What is Stoke Therapeutics's growth rate over time
Valuation
What is Stoke Therapeutics stock price valuation
P/E
10.58
P/B
1.39
P/S
2.72
EV/EBIT
5.62
EV/EBITDA
5.04
EV/Sales
1.13
The EPS has soared by 152% from the previous quarter and by 135% YoY
Stoke Therapeutics's equity has soared by 149% YoY and by 53% from the previous quarter
The P/B is 58% below the 5-year quarterly average of 3.3 and 40% below the last 4 quarters average of 2.3
The price to sales (P/S) is 90% lower than the last 4 quarters average of 27.3
Efficiency
How efficient is Stoke Therapeutics business performance
STOK's ROA has soared by 148% from the previous quarter and by 134% YoY
The ROE has soared by 145% since the previous quarter and by 129% year-on-year
STOK's return on invested capital has surged by 127% since the previous quarter and by 106% year-on-year
The ROS has soared by 107% from the previous quarter and by 101% YoY
Dividends
What is STOK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for STOK.
Financial health
How did Stoke Therapeutics financials performed over time
STOK's total assets has soared by 98% YoY and by 50% from the previous quarter
Stoke Therapeutics's quick ratio has soared by 59% YoY and by 48% from the previous quarter
STOK's debt is 100% smaller than its equity
Stoke Therapeutics's equity has soared by 149% YoY and by 53% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.